MedTrace Logo

Evaluation of Type I IFN Level and Disease Activity in SLE Patients

NCT05446428 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2022-07-06

No results posted yet for this study

Summary

Elevated level of IFN type I in SLE patients associated with certain serum biomarkers (galectin -1,-3,-9; cytokine profile - 20 plex panel - GM-CSF, IFN-γ, IL-2, -4,-5,-6,-7,-8,-10,-13,-15,-17,-18, IP-10. MCP-1, MIG, MIP-1α, MIP-1β, RANTES, TNF-α, TNF-RII, BAFF, APRIL), clinical and laboratory manifestations, activity and duration pf the disease and SLE patients quality of life. Standard immunosuppressive and anti-B-cell therapy can reduce the IFN type I and associated biomarkers levels in patients with high and moderate disease activity (SLEDAI-2К ≥6).

Conditions

  • Elevated Level of IFN Type I in SLE Patients

Interventions

OTHER

study of IFNGS expression biomarkers

Blood tests for serum biomarkers, autoantibodies, cytokine profile etc.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • V.A. Nasonova Research Institute of Rheumatology, Moscow

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-12-31
Completion
2024-07-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05446428 on ClinicalTrials.gov